Home

News

Scope Fluidics Group’s SPV enters into cooperation with Technicolor Precision BioDevices (Technicolor Poland)

3 August 2021

Bacteromic sp. z o.o., a member of the Scope Fluidics group developing innovative medical diagnostic devices, has signed...

Read More

Scope Fluidics launches clinical trials of the BacterOMIC system in second external laboratory

10 June 2021

Scope Fluidics – a biotechnological company listed on NewConnect, developer of innovative medical diagnostics projects – begins validation...

Read More

Another SPV of Scope Fluidics with positive recommendation regarding ISO 13485:2016 compliance certification

19 April 2021

Bacteromic – a member of the Scope Fluidics S.A. Capital Group – has successfully passed the ISO certification...

Read More

Scope Fluidics has commenced the verification of the BacterOMIC system, which is one of the elements of the preregistration procedure

13 January 2021

Bacteromic – a member of the Scope Fluidics S.A. Capital Group – has announced the commencement of the...

Read More

Scope Fluidics obtains another European patent protecting the BacterOMIC technology

16 December 2020

Bacteromic – a member of the Scope Fluidics S.A. Capital Group – has received a conditional decision from...

Read More

Scope Fluidics launches a manufacturing line for the Bacteromic system

5 October 2020

Scope Fluidics – a biotechnological company listed on NewConnect, owner of innovative medical diagnostics projects – has completed...

Read More

Bacteromic obtains the first European patent for the technology for rapid determination of antibiotic resistance of bacteria

7 August 2020

Bacteromic – a member of the Scope Fluidics S.A. Capital Group – announced that it has received a conditional decision from the European Patent Office (EPO) to grant a patent...

Read More

Scope Fluidics launches the BacterOMIC system prevalidation process

14 April 2020

Bacteromic – a member of the Scope Fluidics S.A. Capital Group – is working according to the assumed schedule and has announced

Read More

BacterOMIC project awarded again

27 March 2020

Paweł Dębski, PhD, Eng. from Scope Fluidics was among the winners of the international training competition “V4 Innovators in Israel Training Program”.

Read More

Scope Fluidics ready for BacterOMIC system industrialisation

15 January 2020

Bacteromic – a member of the Scope Fluidics S.A. Capital Group – announced the completion of another, fourth milestone of the BacterOMIC project,

Read More

Scope Fluidics successfully tested the BacterOMIC system at the Microbiology Department of the National Tuberculosis and Lung Diseases Research Institute

9 December 2019

Bacteromic – a member of the Scope Fluidics S.A. Capital Group – has successfully completed the second series of external pre-validation tests of the BacterOMIC

Read More

Scope Fluidics obtains €1.93 million of Horizon 2020 funding for the BacterOMIC project

25 July 2019

Bacteromic – a company which belongs to the Scope Fluidics S.A. Capital Group – has announced that it received a positive recommendation for funding under Phase 2

Read More

Two Scope Fluidics projects among the most ground-breaking diagnostic products in the American Association for Clinical Chemistry competition

26 April 2019

PCR|ONE and BacterOMIC, two innovative medical diagnostic systems developed by Scope Fluidics, a biotechnology company listed on NewConnect

Read More

Scope Fluidics aspiring to be awarded a prestigious Horyzont 2020 grant

27 February 2019

Bacteromic – a company owned by Scope Fluidics S.A. Capital Group – is applying for funding for the BacterOMIC project under Phase 2 of the European SME

Read More

European Patent Office issues a positive opinion for the patent application regarding BacterOMIC system

22 February 2019

Bacteromic Sp. z o.o., a company that belongs to the Scope Fluidics S.A. Capital Group, received from the European Patent Office (EPO) a „European search report” and a written opinion

Read More

Scope Fluidics completes the validation of BacterOMIC system’s functionality

29 January 2019

Bacteromic, a company that belongs to the Scope Fluidics S.A. Capital Group, has reached another milestone of the BacterOMIC project. The primary assumption of this stage of works was to...

Read More

Completion of the first tests of the BacterOMIC system in the National Medicines Institute

29 November 2018

Bacteromic, a subsidiary of Scope Fluidics – a biotechnological company listed on the NewConnect stock exchange, concluded the first tests of functionality of a prototype of the BacterOMIC system

Read More

Scope Fluidics begins first tests of the BacterOMIC system

27 August 2018

Scope Fluidics – a biotechnological company listed on the NewConnect stock exchange and an owner of innovative medical diagnostics projects – entered into cooperation with the National Medicines Institute (NIL).

Read More

Completion of a stage of works on the Bacteromic project

3 April 2018

The Management Board of Scope Fluidics S.A. (the “Company”) would like to announce that the second stage of R&D works on the Bacteromic system has been completed, in line with...

Read More

Completion of the first stage of the Bacteromic project

2 October 2017

Management Board of Scope Fluidics S.A. (the “Company”) would like to announce that the first stage of R&D works on the Bacteromic system has been completed, in line with the...

Read More

Scope Fluidics Group’s SPV enters into cooperation with Technicolor Precision BioDevices (Technicolor Poland)

3 August 2021

Bacteromic sp. z o.o., a member of the Scope Fluidics group developing innovative medical diagnostic devices, has signed...

Read More

Scope Fluidics launches clinical trials of the BacterOMIC system in second external laboratory

10 June 2021

Scope Fluidics – a biotechnological company listed on NewConnect, developer of innovative medical diagnostics projects – begins validation...

Read More

Another SPV of Scope Fluidics with positive recommendation regarding ISO 13485:2016 compliance certification

19 April 2021

Bacteromic – a member of the Scope Fluidics S.A. Capital Group – has successfully passed the ISO certification...

Read More

Scope Fluidics has commenced the verification of the BacterOMIC system, which is one of the elements of the preregistration procedure

13 January 2021

Bacteromic – a member of the Scope Fluidics S.A. Capital Group – has announced the commencement of the...

Read More

Scope Fluidics obtains another European patent protecting the BacterOMIC technology

16 December 2020

Bacteromic – a member of the Scope Fluidics S.A. Capital Group – has received a conditional decision from...

Read More

Scope Fluidics launches a manufacturing line for the Bacteromic system

5 October 2020

Scope Fluidics – a biotechnological company listed on NewConnect, owner of innovative medical diagnostics projects – has completed...

Read More

Bacteromic obtains the first European patent for the technology for rapid determination of antibiotic resistance of bacteria

7 August 2020

Bacteromic – a member of the Scope Fluidics S.A. Capital Group – announced that it has received a conditional decision from the European Patent Office (EPO) to grant a patent...

Read More

Scope Fluidics launches the BacterOMIC system prevalidation process

14 April 2020

Bacteromic – a member of the Scope Fluidics S.A. Capital Group – is working according to the assumed schedule and has announced

Read More

BacterOMIC project awarded again

27 March 2020

Paweł Dębski, PhD, Eng. from Scope Fluidics was among the winners of the international training competition “V4 Innovators in Israel Training Program”.

Read More

Scope Fluidics ready for BacterOMIC system industrialisation

15 January 2020

Bacteromic – a member of the Scope Fluidics S.A. Capital Group – announced the completion of another, fourth milestone of the BacterOMIC project,

Read More

Scope Fluidics successfully tested the BacterOMIC system at the Microbiology Department of the National Tuberculosis and Lung Diseases Research Institute

9 December 2019

Bacteromic – a member of the Scope Fluidics S.A. Capital Group – has successfully completed the second series of external pre-validation tests of the BacterOMIC

Read More

Scope Fluidics obtains €1.93 million of Horizon 2020 funding for the BacterOMIC project

25 July 2019

Bacteromic – a company which belongs to the Scope Fluidics S.A. Capital Group – has announced that it received a positive recommendation for funding under Phase 2

Read More

Two Scope Fluidics projects among the most ground-breaking diagnostic products in the American Association for Clinical Chemistry competition

26 April 2019

PCR|ONE and BacterOMIC, two innovative medical diagnostic systems developed by Scope Fluidics, a biotechnology company listed on NewConnect

Read More

Scope Fluidics aspiring to be awarded a prestigious Horyzont 2020 grant

27 February 2019

Bacteromic – a company owned by Scope Fluidics S.A. Capital Group – is applying for funding for the BacterOMIC project under Phase 2 of the European SME

Read More

European Patent Office issues a positive opinion for the patent application regarding BacterOMIC system

22 February 2019

Bacteromic Sp. z o.o., a company that belongs to the Scope Fluidics S.A. Capital Group, received from the European Patent Office (EPO) a „European search report” and a written opinion

Read More

Scope Fluidics completes the validation of BacterOMIC system’s functionality

29 January 2019

Bacteromic, a company that belongs to the Scope Fluidics S.A. Capital Group, has reached another milestone of the BacterOMIC project. The primary assumption of this stage of works was to...

Read More

Completion of the first tests of the BacterOMIC system in the National Medicines Institute

29 November 2018

Bacteromic, a subsidiary of Scope Fluidics – a biotechnological company listed on the NewConnect stock exchange, concluded the first tests of functionality of a prototype of the BacterOMIC system

Read More

Scope Fluidics begins first tests of the BacterOMIC system

27 August 2018

Scope Fluidics – a biotechnological company listed on the NewConnect stock exchange and an owner of innovative medical diagnostics projects – entered into cooperation with the National Medicines Institute (NIL).

Read More

Completion of a stage of works on the Bacteromic project

3 April 2018

The Management Board of Scope Fluidics S.A. (the “Company”) would like to announce that the second stage of R&D works on the Bacteromic system has been completed, in line with...

Read More

Completion of the first stage of the Bacteromic project

2 October 2017

Management Board of Scope Fluidics S.A. (the “Company”) would like to announce that the first stage of R&D works on the Bacteromic system has been completed, in line with the...

Read More